Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph H Golec

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Correctly measuring drug development risk: a public policy imperativeJohn A Vernon, Joseph H Golec
Managed Care (Langhorne, Pa.)|August 12, 2004
Pharmaceutical reimportation: the European experience--what the United States can expectJoseph H Golec, John A Vernon
Pharmacoeconomics|July 8, 2011
The case for less, not more, US FDA regulationJohn A Vernon, Joseph H Golec
Expert Review of Clinical Pharmacology|January 14, 2014
Future of drug development: the economics of pharmacogenomicsJohn A Vernon, Keener Hughen, Joseph H Golec
Pharmacoeconomics|September 14, 2010
Comparative effectiveness regulations and pharmaceutical innovationJohn A Vernon, Joseph H Golec, J Stedman Stevens
American Journal of Law & Medicine|August 25, 2006
The economics of pharmaceutical price regulation and importation: refocusing the debateJohn A Vernon, Joseph H Golec, W Keener Hughen
Health Economics|August 6, 2009
Drug development costs when financial risk is measured using the Fama-French three-factor modelJohn A Vernon, Joseph H Golec, Joseph A Dimasi
Paediatric Drugs|July 11, 2012
Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislationJohn A Vernon, Scott H Shortenhaus, Mark H Mayer, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Correctly measuring drug development risk: a public policy imperativeJohn A Vernon, Joseph H Golec
Managed Care (Langhorne, Pa.)|August 12, 2004
Pharmaceutical reimportation: the European experience--what the United States can expectJoseph H Golec, John A Vernon
Pharmacoeconomics|July 8, 2011
The case for less, not more, US FDA regulationJohn A Vernon, Joseph H Golec
Expert Review of Clinical Pharmacology|January 14, 2014
Future of drug development: the economics of pharmacogenomicsJohn A Vernon, Keener Hughen, Joseph H Golec
Pharmacoeconomics|September 14, 2010
Comparative effectiveness regulations and pharmaceutical innovationJohn A Vernon, Joseph H Golec, J Stedman Stevens
American Journal of Law & Medicine|August 25, 2006
The economics of pharmaceutical price regulation and importation: refocusing the debateJohn A Vernon, Joseph H Golec, W Keener Hughen
Health Economics|August 6, 2009
Drug development costs when financial risk is measured using the Fama-French three-factor modelJohn A Vernon, Joseph H Golec, Joseph A Dimasi
Paediatric Drugs|July 11, 2012
Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislationJohn A Vernon, Scott H Shortenhaus, Mark H Mayer, et al.
Pageof 1